Chenyue Lu
Overview
Explore the profile of Chenyue Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nguyen N, Wan G, Ugwu-Dike P, Alexander N, Raval N, Zhang S, et al.
J Am Acad Dermatol
. 2023 Feb;
88(6):1308-1316.
PMID: 36828138
Background: Emerging evidence suggests that cutaneous immune-related adverse events (cirAEs) are associated with a survival benefit in the setting of advanced melanoma treated with immune checkpoint inhibitor (ICI) therapy. Previous...
12.
Neyaz A, Rickelt S, Yilmaz O, Parrack P, Lu C, Yilmaz O, et al.
J Clin Pathol
. 2023 Feb;
76(9):582-590.
PMID: 36823143
Aims: The lack of accepted scoring criteria has precluded the use of p53 in routine practice. We evaluate the utility of automated quantitative p53 analysis in risk stratifying Barrett's oesophagus...
13.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, et al.
J Am Acad Dermatol
. 2023 Feb;
88(5):1024-1032.
PMID: 36736626
Background: Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear. Objective: To investigate the...
14.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, et al.
medRxiv
. 2023 Jan;
PMID: 36711758
Background: Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear. Objective: To investigate the...
15.
Lu C, Jin D, Palmer N, Fox K, Kohane I, Smoller J, et al.
Transl Psychiatry
. 2022 Apr;
12(1):154.
PMID: 35410453
Schizophrenia affects >3.2 million people in the USA. However, its comorbidity patterns have not been systematically characterized in real-world populations. To address this gap, we conducted an observational study using...
16.
Rajurkar M, Parikh A, Solovyov A, You E, Kulkarni A, Chu C, et al.
Cancer Discov
. 2022 Mar;
12(6):1462-1481.
PMID: 35320348
Significance: Colorectal cancers express abundant repeat elements that have a viral-like life cycle that can be therapeutically targeted with nucleoside reverse transcriptase inhibitors (NRTI) commonly used for viral diseases. NRTIs...
17.
Krishnan B, Yasuhara T, Rumde P, Stanzione M, Lu C, Lee H, et al.
J Cell Biol
. 2022 Jan;
221(3).
PMID: 35019938
RB restricts G1/S progression by inhibiting E2F. Here, we show that sustained expression of active RB, and prolonged G1 arrest, causes visible changes in chromosome architecture that are not directly...
18.
Gill T, Wang H, Bandaru R, Lawlor M, Lu C, Nieman L, et al.
Oncogene
. 2021 Oct;
40(47):6527-6539.
PMID: 34650218
MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal...
19.
Guo H, Golczer G, Wittner B, Langenbucher A, Zachariah M, Dubash T, et al.
Mol Cell
. 2021 Oct;
81(19):4041-4058.e15.
PMID: 34624217
Deregulation of oncogenic signals in cancer triggers replication stress. Immediate early genes (IEGs) are rapidly and transiently expressed following stressful signals, contributing to an integrated response. Here, we find that...
20.
Pahalyants V, Murphy W, Klebanov N, Lu C, Theodosakis N, Klevens R, et al.
J Am Acad Dermatol
. 2021 Sep;
86(1):252-255.
PMID: 34509536
No abstract available.